. 2017 Apr 7;10:2057–2066. doi: 10.2147/OTT.S113598

Table 1.

Efficacy of bevacizumab-based combinations across MPM trials

First author	Jackman et al²⁶	Kindler et al²⁷		Ceresoli et al²⁹	Dowell et al³⁰	Zalcman et al³¹
Treatment	Bev + erlotinib	Gem + cis		Carbo + pem + bev	Cis + pem + bev (MPM patients)	Cis + pem
Treatment	Bev + erlotinib	+Bev	−Bev	Carbo + pem + bev	Cis + pem + bev (MPM patients)	+Bev	−Bev
PFS (months)	2.2^a	6.9	6.0	6.9	6.9	9.2	7.3
OS (months)	5.8	15.6	14.7	15.3	14.8	18.8	16.1

Note:

Only median time to progression was reported.

Abbreviations: bev, bevacizumab; carbo, carboplatin; cis, cisplatin; gem, gemcitabine; MPM, malignant pleural mesothelioma; OS, overall survival; pem, pemetrexed; PFS, progression-free survival.